About Firefly Bio
Firefly Bio is a company based in San Francisco (United States) founded in 2022 by John Flygare, Carolyn Bertozzi, and Bernhard Geierstanger was acquired by Johnson & Johnson in June 2026. Firefly Bio has raised $94 million across 3 funding rounds from investors including Lilly, Johnson & Johnson and HHS. Firefly Bio offers products and services including Degrader Antibody Conjugates and Proprietary Platform. Firefly Bio operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
- Headquarter San Francisco, United States
- Founders John Flygare, Carolyn Bertozzi, Bernhard Geierstanger
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Firefly Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$94 M (USD)
in 3 rounds
-
Latest Funding Round
$94 M (USD), Series A
Dec 18, 2023
-
Investors
Lilly
& 5 more
-
Employee Count
Not available
-
Acquired by
Johnson & Johnson
(Jun 08, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Firefly Bio
Firefly Bio offers a comprehensive portfolio of products and services, including Degrader Antibody Conjugates and Proprietary Platform.
Combines ADCs with protein degraders for targeted tissue delivery.
Enables scalable production and delivery of ADC payloads.
People of Firefly Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Firefly Bio
Firefly Bio has successfully raised a total of $94M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $94 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Firefly Bio
Firefly Bio has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Johnson & Johnson and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science and technology sectors
|
Locked | Locked | Locked | |
|
Invests in biotech firms developing life-saving drugs and technologies.
|
Locked | Locked | Locked |
Investor details for Firefly Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Firefly Bio
Investment portfolio details for Firefly Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Firefly Bio
Detailed financials for Firefly Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Firefly Bio Comparisons
Peer comparison for Firefly Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Firefly Bio
Firefly Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
Detailed competitors of Firefly Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Firefly Bio
Complete news archive for Firefly Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Firefly Bio
Firefly Bio was founded in 2022.
Firefly Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Scott Hirsch is the current CEO of Firefly Bio.
Firefly Bio is a funded company, having raised a total of $94M across 3 funding rounds to date.
Developer of antibody drug conjugates for the treatment of cancer. The company uses potent catalytic protein degraders as the payloads of ADCs to develop class of therapeutics for a range of intracellular biological targets such as both solid and liquid tumors.
Firefly Bio's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
Firefly Bio offers Degrader Antibody Conjugates and Proprietary Platform.
Firefly Bio has 6 investors. Key investors include Lilly, Johnson & Johnson, HHS, Versant Ventures, and Turmeric Acquisition Corp.